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‘‘The only thing I know is that I
know nothing’’: 5-fluorouracil in
human milk
Women are usually advised to interrupt breastfeeding during
chemotherapy for concerns of serious side-effects to the infant.
However, the passage of cytotoxic drugs in human milk has
been poorly studied.
A 36-year-old woman was diagnosed with rectal cancer while
she was still breastfeeding her 9-month-old son. The tumor was
staged as cT3N1M0 and neoadjuvant 5-flourouracil (5-FU)-based
chemoradiotherapy (CRT) was planned. She was advised to stop
nursing, however, she expressed her desire to resume
breastfeeding after treatment.
After a multidisciplinary discussion, the patient was advised to
pump her breasts twice daily during CRT in order to maintain
milk production. To decide when breastfeeding could be safely
resumed, we evaluated the pharmacokinetics of 5-FU in milk.
The patient received standard CRT with 5-FU 200 mg/m2/day
as i.v. continuous infusion concurrently with pelvic radiotherapy.
Samples of peripheral blood were taken before the start of 5-FU
and after 1, 2 and 5 weeks. Milk samples were obtained before,
during and up to 10 days following the completion of therapy.
5-FU concentrations were measured using an high-
performance liquid chromatography (HPLC) method [1]
modified and optimized for plasma and milk samples. Four
plasma samples were collected and analyzed. The concentration
of 5-FU in plasma ranged between 11.14 and 114.95 lM
(Figure 1A and B). Thirty-three milk samples were collected
and tested. 5-FU levels were undetectable in milk at any time
during and after CRT treatment. To validate the HPLC
methodology used, we carried out parallel analyses on human
milk spiked with different concentrations of 5-FU, which were
stored, extracted and measured in the same conditions. 5-FU
was detected in the validation samples with a limit of detection
at 0.5 lM (Figure1C and D).
The patient completed the planned treatment and eventually
underwent radical surgery without complications. Ten days after
surgery, when pharmacokinetics results were available, the patient
tried to resume breastfeeding, but her infant refused to latch.
Breastfeeding is an essential physiologic process that provides
nutrition and protects the child against infection, immunologic
disorders and some types of cancer during adulthood [2, 3].
Nevertheless and despite the lack of evidence, breastfeeding is
usually not recommended during maternal chemotherapy
because of the potential toxic effects to the infant.
In this case, we report for the first time that 5-FU was
undetectable at any time during and following CRT, although
maternal plasma concentrations reflected normal
pharmacokinetics. The amount of a drug or its metabolites
excreted into milk is dependent upon several factors: lipid
solubility, molecular size, ionization, protein binding and half-
life in maternal plasma [4]. 5-FU has a short half-life and
a high protein bound in serum [5]; these factors probably
accounted for the undetectable levels of 5-FU in milk.
Our results are reassuring, but genetic background and
plasma levels variability might influence 5-FU distribution into
milk. Collecting breast milk for drug assays during and after
chemotherapy, as impractical as this approach may seem, could
provide valuable information to counsel patients receiving
chemotherapy who are willing to resume breastfeeding after the
end of treatment.
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Figure 1. HPLC assay for 5-fluorouracil (5-FU). (A) Representative HPLC-UV chromatograph of 5-FU and chlorouracil (CIU, used as internal
standard) profiles in a plasma sample (note: the numbers near the 5-FU and CIU peaks refer to their specific retention times). (B) Plot of the HPLC-
determined concentration of plasma 5-FU. (C) Representative HPLC-UV chromatograph of 5-FU and CIU (used as internal standard) profiles in 5-
FU-spiked milk samples from a healthy donor. (D) Calibration curve of 5-FU (0.5, 1, 2.5, 5 and 10 lM) obtained in 5-FU-spiked milk from a healthy
donor.
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